Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2016—Thermo Fisher Scientific launched Applied Biosystems TaqPath 1-Step Multiplex PCR Master Mix, a preformulated, universal, 4× concentration master mix designed to deliver sensitive and reproducible detection of up to four RNA (or DNA) targets in a single multiplex reaction.
June 2016—Thermo Fisher Scientific received 510(k) clearance for two new EliA IgG tests for detecting anti-thyroglobulin and anti-thyroid peroxidase autoantibodies in serum or plasma. The CLIA-moderate laboratory tests are performed on the fully automated Phadia 250, 2500, and 5000 laboratory systems.
March 2016—The Thermo Scientific Medifuge is a benchtop centrifuge that features a two-in-one hybrid rotor with interchangeable fixed-angle and swinging buckets to facilitate quick and convenient switching between applications. When coupled with the Thermo Scientific DualSpin rotor, the centrifuge provides the flexibility to perform several applications on a single platform.
December 2015—Thermo Scientific’s DRI Hydrocodone Assay received FDA 510(k) clearance; it also has the requisite sensitivities to meet the newly proposed Substance Abuse and Mental Health Services Administration guidelines (using a 300 ng/mL cutoff). SAMHSA oversees the testing of federally regulated employees, and many organizations follow the guidelines set forth by this agency.
November 2015—Thermo Fisher Scientific received the in vitro diagnostics device CE mark for its Thermo Scientific Prelude MD HPLC, Endura MD mass spectrometer, and ClinQuan MD software.
August 2015—How one pathologist made use of artificial intelligence: Like many pathologists, Jay J. Ye, MD, PhD, longed to spend less time preparing reports and more time interpreting slides and rendering diagnoses. Rather than dedicating half of his workday to what he considers secretarial tasks, the dermatopathologist wanted to devote the lion’s share of his hours in the lab toward applying the knowledge and skills he developed during his years of medical training and practice.
July 2015—Thermo Fisher introduced the Thermo Scientific Orbitrap Fusion Lumos Tribrid Mass Spectrometer, the newest addition to its line of Orbitrap Tribrid mass spectrometers. Designed to expand researchers’ capabilities in advanced proteomics and metabolomics applications, including targeted, data-independent acquisition and top-down analyses, the Orbitrap Fusion Lumos Tribrid has a high level of sensitivity, delivering complete protein sequence coverage and allowing scientists to perform more inclusive analyses.
June 2015—Thermo Fisher Scientific announced the release of the CE-IVD Oncomine Solid Tumour Fusion Transcript kit designed to aid clinical decision-making and enable highly accurate and reliable multiplexed sequencing of formalin-fixed, paraffin-embedded tumor samples.
June 2015—Horizon Discovery Group has signed a supply and commercialization agreement with Thermo Fisher Scientific. Under the terms of the agreement, Thermo Fisher will market and distribute Horizon’s X-MAN human haploid and diploid isogenic cell line collection and will further offer the X-MAN haploid cell line generation service to its worldwide customer base.
May 2015—Thermo Fisher Scientific and Samsung Electronics have formed a strategic collaboration to jointly design, develop, and market new point-of-care solutions in key applications, such as the detection of sepsis, drugs of abuse, and therapeutic drug monitoring as well as the detection of cardiac problems and women’s health conditions.
